Literature DB >> 8612558

Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury in rats.

B J Padanilam1, D R Martin, M R Hammerman.   

Abstract

Pretreatment of rats with insulin-like growth factor I (IGF-I) ameliorates the course of acute ischemic renal injury. Differential display PCR was used to identify genes that are expressed in kidney after induction of acute ischemic renal injury in rats pretreated with vehicle or IGF-I. One amplification product that showed enhanced expression in kidneys of rats rendered ischemic compared to kidneys of sham-operated rats was identified as osteopontin. Sequence analysis of full-length complementary DNAs revealed a single species. Renal tissue was obtained for study 12 h and 1, 2, 3, 5, 7, 14, and 28 days postinjury. Levels of whole kidney osteopontin messenger RNA (mRNA) in rats rendered ischemic 1 day previously were elevated approximately 18-fold compared to levels measured in sham-operated controls, as determined by Northern analysis. No differences were noted 12 h postinjury. Levels of osteopontin mRNA remained elevated for 14 days after ischemia, but were no longer elevated at 28 days. IGF-I pretreatment resulted in enhanced levels of osteopontin mRNA 12 h, 1 day, and 5 days postinjury. In situ hybridization demonstrated that the elevated expression of osteopontin 1 day postinjury was localized predominantly to cells in the distal tubule and medullary thick ascending limb of Henle's loop. Immunostaining showed an identical localization for elevated protein expression. Five days postinjury, osteopontin peptide and mRNA were clearly detected in regenerating proximal tubules in addition to distal tubule and medullary thick ascending limb. We propose that endogenous osteopontin serves to promote tissue regeneration and tissue remodeling within 1 day after acute ischemic injury of kidney. IGF-I enhanced expression of osteopontin at an earlier time postischemia may ameliorate the course of injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612558     DOI: 10.1210/endo.137.5.8612558

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Gene expression analysis in a canine model of X-linked Alport syndrome.

Authors:  Kimberly A Greer; Marnie A Higgins; Melissa L Cox; Timothy P Ryan; Brian R Berridge; Clifford E Kashtan; George E Lees; Keith E Murphy
Journal:  Mamm Genome       Date:  2006-09-08       Impact factor: 2.957

2.  Phosphate is a specific signal for induction of osteopontin gene expression.

Authors:  G R Beck; B Zerler; E Moran
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

Review 3.  The role of osteopontin in kidney diseases.

Authors:  Beata Kaleta
Journal:  Inflamm Res       Date:  2018-11-19       Impact factor: 4.575

4.  Osteopontin protects against cardiac ischemia-reperfusion injury through late preconditioning.

Authors:  Yongyi Wang; Baofu Chen; Dafu Shen; Song Xue
Journal:  Heart Vessels       Date:  2009-04-01       Impact factor: 2.037

5.  Osteopontin is induced by TGF-β2 and regulates metabolic cell activity in cultured human optic nerve head astrocytes.

Authors:  Carolin Neumann; Fabian Garreis; Friedrich Paulsen; Christian M Hammer; Marco T Birke; Michael Scholz
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

6.  Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.

Authors:  Christoph Reichetzeder; Karoline von Websky; Oleg Tsuprykov; Azadeh Mohagheghi Samarin; Luise Gabriele Falke; Sulistyo Emantoko Dwi Putra; Ahmed Abdallah Hasan; Viktoriia Antonenko; Caterina Curato; Jörg Rippmann; Thomas Klein; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2017-06-07       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.